296 related articles for article (PubMed ID: 23089633)
21. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
de Rojas I; Romero J; Rodríguez-Gomez O; Pesini P; Sanabria A; Pérez-Cordon A; Abdelnour C; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Alegret M; Espinosa A; Ortega G; Gil S; Guitart M; Gailhajanet A; Santos-Santos MA; Moreno-Grau S; Sotolongo-Grau O; Ruiz S; Montrreal L; Martín E; Pelejà E; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MA; Giménez J; Pérez-Grijalba V; Marquié GM; Monté-Rubio G; Valero S; Orellana A; Tárraga L; Sarasa M; Ruiz A; Boada M;
Alzheimers Res Ther; 2018 Nov; 10(1):119. PubMed ID: 30497535
[TBL] [Abstract][Full Text] [Related]
22. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
Resnick SM; Bilgel M; Moghekar A; An Y; Cai Q; Wang MC; Thambisetty M; Prince JL; Zhou Y; Soldan A; Wong DF; O'Brien RJ; Ferrucci L; Albert MS
Neurobiol Aging; 2015 Aug; 36(8):2333-9. PubMed ID: 26004017
[TBL] [Abstract][Full Text] [Related]
23. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
[TBL] [Abstract][Full Text] [Related]
24. Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects.
Squarzoni P; Faria DP; Yassuda MS; Porto FHG; Coutinho AM; Costa NAD; Nitrini R; Forlenza OV; Duran FLS; Brucki SMD; Buchpiguel CA; Busatto GF
J Alzheimers Dis; 2020; 78(1):229-244. PubMed ID: 32986673
[TBL] [Abstract][Full Text] [Related]
25. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
26. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
27. Disrupted Intrinsic Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer's Disease.
Koch K; Myers NE; Göttler J; Pasquini L; Grimmer T; Förster S; Manoliu A; Neitzel J; Kurz A; Förstl H; Riedl V; Wohlschläger AM; Drzezga A; Sorg C
Cereb Cortex; 2015 Dec; 25(12):4678-88. PubMed ID: 24996404
[TBL] [Abstract][Full Text] [Related]
28. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
29. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
[TBL] [Abstract][Full Text] [Related]
30. Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer's disease.
Park JC; Han SH; Lee H; Jeong H; Byun MS; Bae J; Kim H; Lee DY; Yi D; Shin SA; Kim YK; Hwang D; Lee SW; Mook-Jung I
Prog Neurobiol; 2019 Dec; 183():101690. PubMed ID: 31605717
[TBL] [Abstract][Full Text] [Related]
31. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
Tzen KY; Yang SY; Chen TF; Cheng TW; Horng HE; Wen HP; Huang YY; Shiue CY; Chiu MJ
ACS Chem Neurosci; 2014 Sep; 5(9):830-6. PubMed ID: 25054847
[TBL] [Abstract][Full Text] [Related]
32. Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease.
Chételat G; Villemagne VL; Pike KE; Ellis KA; Ames D; Masters CL; Rowe CC;
Neurodegener Dis; 2012; 10(1-4):141-4. PubMed ID: 22301812
[TBL] [Abstract][Full Text] [Related]
33. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
34. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846
[TBL] [Abstract][Full Text] [Related]
35. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
36. Imaging beta-amyloid burden in aging and dementia.
Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL
Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554
[TBL] [Abstract][Full Text] [Related]
37. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
Van Hooren RWE; Riphagen JM; Jacobs HIL;
Alzheimers Res Ther; 2018 Aug; 10(1):88. PubMed ID: 30153858
[TBL] [Abstract][Full Text] [Related]
38. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
39. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
40. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]